ATX · ASX

Amplia Therapeutics Ltd. (ASX:ATX)

AU$0.2

 -0.02 (-9.091%)
ASX:Live
30/06/2025 04:10:08 PM
Volume Spike HALO Price Momentum HALO Ords GROWTH AUS Big Candle +1
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

ATX Overview

ATX Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Weak

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About ATX

Website

Amplia Therapeutics Ltd.

Telephone

61.3.9123.1140

Address

Level 17 350 Queen Street Melbourne, Victoria (VIC) 3000

Description

Amplia Therapeutics Ltd. is a medical biotechnology company, which engages in the development of drugs for potential use in multiple indications including oncology and chronic fibrosis. Its immuno-modulator microparticles technology can be used to induce the human immune system to fight certain cancers and infections, or modulate certain immune mechanisms implicated in autoimmune diseases such as multiple sclerosis. The company was founded by Christopher J. Burns on May 31, 2000 and is headquartered in Melbourne, Australia.

ATX Price Chart

Key Stats

Market Cap

AU$75.65M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.05 - 0.25

Trade Value (12mth)

AU$54,882.00

1 week

25.71%

1 month

340%

YTD

136.56%

1 year

262.04%

All time high

15.95

Key Fundamentals

EPS 3 yr Growth

-10.50%

EBITDA Margin

N/A

Operating Cashflow

-$7m

Free Cash Flow Return

-42.40%

ROIC

-40.50%

Interest Coverage

-187.70

Quick Ratio

7.90

Other Data

Shares on Issue (Fully Dilluted)

365m

HALO Sector

Healthcare

Next Company Report Date

N/A

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

ATX Announcements

Latest Announcements

Date Announcements

24 June 25

Amplia Gains US Ethics Approval for Pancreatic Cancer Trial

×

Amplia Gains US Ethics Approval for Pancreatic Cancer Trial

19 June 25

Second Complete Response in ACCENT Pancreatic Cancer Trial

×

Second Complete Response in ACCENT Pancreatic Cancer Trial

19 June 25

Change in substantial holding

×

Change in substantial holding

16 June 25

Pathological Complete Response in Pancreatic Cancer Trial

×

Pathological Complete Response in Pancreatic Cancer Trial

30 May 25

Preliminary Final Report and Annual Report YE 31 March 2025

×

Preliminary Final Report and Annual Report YE 31 March 2025

30 May 25

2025 Corporate Governance Statement

×

2025 Corporate Governance Statement

30 May 25

Appendix 4G - Key to Corporate Governance Disclosures

×

Appendix 4G - Key to Corporate Governance Disclosures

16 May 25

Change in substantial holding

×

Change in substantial holding

15 May 25

ACCENT Trial Achieves Superiority over Chemotherapy Alone

×

ACCENT Trial Achieves Superiority over Chemotherapy Alone

12 May 25

Amplia Appoints Dr Jason Lickliter as Chief Medical Officer

×

Amplia Appoints Dr Jason Lickliter as Chief Medical Officer

30 April 25

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

28 April 25

ACCENT Data Update Presented at International Conference

×

ACCENT Data Update Presented at International Conference

09 April 25

US Clinical Trial Activities for Narmafotinib Now Underway

×

US Clinical Trial Activities for Narmafotinib Now Underway

27 March 25

Encouraging Updated Data from Pancreatic Cancer Trial

×

Encouraging Updated Data from Pancreatic Cancer Trial

03 March 25

Type D Meeting Outcome With US Food And Drug Administration

×

Type D Meeting Outcome With US Food And Drug Administration

13 February 25

Listing Rule 3.11.2 - change of Exercise Price of Options

×

Listing Rule 3.11.2 - change of Exercise Price of Options

31 January 25

Completion of Recruitment of ACCENT Trial

×

Completion of Recruitment of ACCENT Trial

30 January 25

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

20 January 25

New Narmafotinib Data Presented at International Conference

×

New Narmafotinib Data Presented at International Conference

10 January 25

Release of Shares from Voluntary Escrow

×

Release of Shares from Voluntary Escrow

23 December 24

Security Class Reinstatement to Quotation - ATXOA

×

Security Class Reinstatement to Quotation - ATXOA

20 December 24

Notification regarding unquoted securities - ATX

×

Notification regarding unquoted securities - ATX

20 December 24

Application for quotation of securities - ATX

×

Application for quotation of securities - ATX

20 December 24

Application for quotation of securities - ATX

×

Application for quotation of securities - ATX

ATX Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.03 -0.02 -0.02 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.03 -0.02 -0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock -28.5 28.0 3.2 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.03 -0.02 -0.02 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.03 -0.03 -0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock -66.3 27.3 23.0 Lock Lock Lock
     Yield % Lock Lock Lock Lock -32.2 -34.3 -32.0 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.08 0.06 0.05 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.04 0.02 0.03 Lock Lock Lock
     Growth % Lock Lock Lock Lock -43.3 -55.9 97.4 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 204 204 307 Lock Lock Lock
Basic m Lock Lock Lock Lock 204 204 307 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 7 9 10 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -2,186.3 -17.4 0.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -7 -9 -10 Lock Lock Lock
     Growth % Lock Lock Lock Lock -31.6 -20.7 -17.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -7 -9 -11 Lock Lock Lock
     Growth % Lock Lock Lock Lock -32.8 -20.7 -17.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -7 -9 -10 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -1 -4 -4 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -6 -5 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -71.3 27.9 -45.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -5 -5 -7 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 0 -1 14 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -5 -5 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock -20.2 3.4 -34.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 9 3 11 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 19 15 23 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -7 -2 -11 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 3 3 2 Lock Lock Lock
Equity $m Lock Lock Lock Lock 16 11 21 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 16 11 21 Lock Lock Lock
     Growth % Lock Lock Lock Lock -33.5 -28.2 83.9 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -33.4 -30.3 -28.7 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -39.4 -39.4 -31.3 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -35.6 -58.1 -62.2 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -31.3 -32.9 -40.5 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -26.5 -37.5 -42.4 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Leverage
Interest Cover X Lock Lock Lock Lock -137.5 -113.9 -187.7 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.9 0.2 1.0 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -44.1 -16.0 -51.6 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 3.8 2.0 7.9 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 3.8 2.0 7.9 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 88.1 50.1 72.8 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -192.3 -150.6 -364.7 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -33.4 -30.3 -28.7 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.2 1.3 1.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -39.4 -39.4 -31.3 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -39.4 -39.4 -31.3 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 1,781.4 4,133.6 6,746.8 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -1,781.4 -4,133.6 -6,746.8 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

ATX Shortsell

Frequently Asked Questions

The current share price of Amplia Therapeutics Ltd. (ATX:ASX) is AU$0.2.
The 52-week high share price for Amplia Therapeutics Ltd. (ATX:ASX) is AU$0.25.
The 52-week low share price for Amplia Therapeutics Ltd. (ATX:ASX)? is AU$0.05.
Amplia Therapeutics Ltd. (ATX:ASX) does not pay a dividend.
Amplia Therapeutics Ltd. (ATX:ASX) does not pay a dividend.
Amplia Therapeutics Ltd. (ATX:ASX) has a franking level of 0.0%.
Amplia Therapeutics Ltd. (ATX:ASX) is classified in the Healthcare.
The current P/E ratio for Amplia Therapeutics Ltd. (ATX:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.